Antibody Therapeutics Market Size, Share, Trends, Demand, Growth and Competitive Outlook | F. Hoffmann-La Roche Ltd., (Switzerland) AbbVie Inc

Global Antibody Therapeutics Market Size, Status, and forecast for the 2025-2032. The research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Antibody Therapeutics Market industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial data. Additionally, the report includes upstream and downstream analyses of key players, as well as global certainties and assurances. The report evaluates dynamic aspects such as forecast market information, Porter's Five Forces Analysis, sales estimates, wide product portfolio, market scenarios, and possibility studies.

The global antibody therapeutics market, valued at US$217.7 billion in 2023, is forecasted to grow at a robust CAGR of 14.2%, reaching US$247.3 billion in 2024 and an impressive US$479.0B billion by 2032.

Updated Version of Sample Report Included:
https://www.marketdigits.com/request/sample/4192

Global Antibody Therapeutics Market Dynamics

Antibody Therapeutics Market Drivers:

Antibody engineering is a specialized field that focuses on modifying antibodies to enhance their therapeutic properties. This process involves the application of technology and techniques to design antibodies with specific characteristics tailored for therapeutic applications. Antibody engineering offers several benefits such as customization for specific therapeutic indications, targeted effects and more. Severa antibody engineering techniques are being used for the production of antibody fragments. These include hybridoma technology, Phage Display, Single B-Cell Technology, and Transgenic Animals. Wacker's ESETEC secretion technology (by Wacker Chemie AG) is an approach for the expression and secretion of antibody fragments (Fab) exceeding 4.0 g/L and scFv exceeding 3.5 g/L into the fermentation broth. Another platform for the productive creation of a sizable number of antibody fragments is the Pelican Expression Technology Platform (by Ligand Pharmaceuticals) and the pOP prokaryotic expression vector. Such advancements in technology allow the development of novel antibody therapeutics, thus, supporting market growth.

Antibody Therapeutics Market Restraint:

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the major regulatory authorities that regulate the commercialization of antibody therapeutics. The stringent regulatory guidelines imposed by the FDA in the US and the EMA in Europe during clinical trials have the potential to create significant restraints for companies. There have been instances of product regulatory rejections or withdrawals due to stringent regulatory parameters for antibody therapeutics. For instance, in December 2022, Y-mAbs Therapeutics issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine 131I-omburtamab (omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma for which the FDA completed the review of the application and concluded that it is unable to approve the BLA in its then presented form. Thus, the market players are required to mandatorily follow regulations put forth by the regulatory bodies to overcome this restraint.

Major Players in Antibody Therapeutics Markets are:

F. Hoffmann-La Roche Ltd. (Switzerland) AbbVie Inc. (US) Johnson & Johnson (US) Merck KGaA (Germany) Bristol-Myers Squibb (US) AstraZeneca (UK) Sanofi (France) Regeneron Pharmaceuticals Inc. (US) Novartis AG (Switzerland) Amgen Inc. (US) Biogen Inc. (US)

Industry News:

In October 2023, F. Hoffmann-La Roche Ltd. entered into a definitive agreement to acquire Televant. Through this agreement, Roche received the development, manufacturing and commercialization rights in the US and Japan for Telavant's RVT-3101, a novel TL1A directed antibody.

In January 2023, AbbVie Inc. and Immunome, Inc. entered into strategic collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine.

In December 2022, AbbVie Inc. and HotSpot Therapeutics entered into a strategic collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.

"Connect with our team of research specialists and unlock the optimal solution for driving your business growth"

Global Antibody Therapeutics Market Segmentation:

By Type:
Monoclonal Antibodies
o Oncology, Autoimmune Disease
o Infectious Disease
o Other
Antibody Drug Conjugates

By End User:
Hospitals
Specialty Centers
Others

Know more about this report:
https://www.marketdigits.com/antibody-therapeutics-market-1708503695

The following areas and countries are covered in the worldwide Antibody Therapeutics Market file:

North America (US, Canada, Mexico)
Europe (Germany, France, UK, Russia, Italy)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Saudi Arabia, UAE), Egypt, Nigeria, and South Korea)

The market was dominated by North America in 2022 and this dominance is anticipated to continue throughout the forecast period between 2023 and 2028. The market for antibody therapeutics is expanding in the region as a result of factors like major antibody therapeutics sales revenue generated from the region and availability of advanced infrastructure in hospitals among others.

Detailed industry forecast-Brief Introduction to the research report:

Additional information on company participants
Customized reports and analyst assistance are available upon request.
Recent market developments and potential future growth opportunities
Personalized regional/country reports upon request
New data sources are being integrated.
Increased focus on data privacy and security
Increased collaboration and co-creation

Discover More: Visit Our Website for Additional Reports!

https://www.marketdigits.com/car-finance-market-1694177145

https://www.marketdigits.com/automotive-dashboard-camera-market-1694177145

https://www.marketdigits.com/railway-traction-motor-market-1694177145

https://www.marketdigits.com/tower-crane-market-1694177145

https://www.marketdigits.com/aerospace-materials-market-1694177145

About Us

Founded in 2015, MarketDigits Consulting & Advisory Pvt Ltd is a leading business research and consulting firm. Our mission is to empower clients by identifying emerging opportunities and driving revenue growth across industries. We specialize in providing comprehensive market insights, advanced technology solutions, and actionable strategies that support operational and strategic decision-making.

With a focus on the full value chain, our expert team delivers high-quality syndicate research reports, proprietary databases, and consulting services to help clients navigate today's competitive and dynamic business environment. At MarketDigits, we use advanced analysis to uncover profitable opportunities, enabling businesses to make smart decisions and achieve sustainable success.

Contact Us:

+1 510-730-3200 | +1 276-206-2055

sales@marketdigits.com

1248 CarMia Way Richmond

VA 23235, United States

This release was published on openPR.